---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ONWARD1"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ONWARD1. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/onward1"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ONWARD1

<a id="heading-3.1.1"></a>

## 3.1.1 ONWARD1

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Objective and questions in the ClinicalTrials.gov record

> “The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis.”
> “Does ESK-001 reduce the severity of people's psoriasis?”
> “How safe is ESK-001 in people with moderate to severe plaque psoriasis?”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.1-2"></a>

#### Objective of the ONWARD1 and ONWARD2 congress presentation

> “To evaluate the efficacy, safety, onset of action, and patient-reported outcomes of envudeucitinib vs placebo and apremilast in adults with moderate-to-severe plaque psoriasis through Week 24”

Source: [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2024-07-25”
> “Primary Completion (Actual) 2025-09-19”
> “Study Completion (Actual) 2025-11-20”
> “First Posted 2024-09-19”
> “Last Update Posted 2026-10-28”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.2-2"></a>

#### Completion dates estimated at registration, September 2024, superseded in June 2025

> “Primary Completion 2026-05 [Estimated]”
> “Study Completion 2026-06 [Estimated]”

Source: [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)

<a id="topic-3.1.1.2-3"></a>

#### Results posting status and certification date in the ClinicalTrials.gov record

> “No Results Posted”
> “Certification/Extension First Submitted 2026-08-06”
> “Certification/Extension First Posted 2026-08-10”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.2-4"></a>

#### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 156 locations”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

| Country | First site listed for the country in the record |
| --- | --- |
| United States | “Phoenix, Arizona, United States, 85032” |
| Australia | “Kogarah, New South Wales, Australia, 2217” |
| Bulgaria | “Gabrovo, Bulgaria, 5300” |
| Canada | “Edmonton, Alberta, Canada, T5J 3S9” |
| Czechia | “Kutná Hora, Czechia, 28401” |
| Germany | “Tübingen, Baden-Wurttemberg, Germany, 72070” |
| Japan | “Fukuoka, Fukuoka-shi, Japan, 814-0180” |
| Poland | “Gdansk, Poland, 80-546” |
| Portugal | “Lisbon, Portugal, 1998-018” |
| South Korea | “Busan, South Korea, 49241” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.2-5"></a>

#### Country removed from the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Removed location countries (`removedCountries`) | “Belgium” |

Source: [ClinicalTrials.gov NCT06586112 API record](https://clinicaltrials.gov/api/v2/studies/NCT06586112)

<a id="topic-3.1.1.2-6"></a>

#### Countries listed for ESK-001-016 and enrollment from Japan in the topline webcast presentation

> “(ESK - 001 - 016) Canada Belgium Bulgaria Australia Portugal Japan Germany Czech Republic United States South Korea Poland”
> “6.1% (56 patients) enrolled from Japan in ESK - 001 - 016 study only”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="topic-3.1.1.2-7"></a>

#### Enrollment period and number of sites across ONWARD1 and ONWARD2

> “1700+ patients enrolled at >270 study sites in 10 months”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

> “Completed patient enrollment in the pivotal Phase 3 global ONWARD clinical program of envu for the treatment of moderate-to-severe plaque psoriasis”

Source: [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)”
> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”
> “The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis).”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.3-2"></a>

#### Parallel 24-week design of ONWARD1 and ONWARD2

> “The Phase 3 ONWARD clinical program includes two parallel global, multicenter, randomized, double-blind, placebo- and active-comparator-controlled 24-week trials—ONWARD1 (NCT06586112) and ONWARD2 (NCT06588738)—evaluating the efficacy and safety of envudeucitinib in adults with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.1.3-3"></a>

#### Replicate design of ONWARD1 and ONWARD2

> “Replicate design; actual enrollment is reported as ONWARD1 (NCT06586112); ONWARD2 (NCT06588738).”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Placebo rollover to envudeucitinib at week 16 and treatment periods in the design schematic

> “Placebo (N= 210 ) Wk 16 : Rollover to envudeucitinib”
> “ONWARD1 and ONWARD2: 24 - week duration, placebo and active comparator (apremilast) controlled”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="topic-3.1.1.3-5"></a>

#### Eligibility for the ONWARD3 long-term extension after week 24

> “Patients completing Week 24 were eligible to enter ONWARD3 (NCT06846541), an ongoing long-term extension study assessing durability, greater maintenance of response, and long-term safety.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Participants with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-3"></a>

#### Washout periods and prior treatment response in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-4"></a>

#### Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in November 2024

> “Any biologic or oral agent targeted to IL-12 or IL-23 within 6 months or any TNFα inhibitor within 2 months or IL-17 within 4 months”

Source: [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)

<a id="topic-3.1.1.4-5"></a>

#### Cardiac, infection, and laboratory exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| QTcF | “Participants with QTcF >450 msec (males) or >470 msec (females) at Screening” |
| Cardiovascular disease | “Unstable cardiovascular disease, defined as a recent clinical deterioration or a cardiac hospitalization within the last 3 months” |
| Herpes zoster and herpes simplex | “Evidence of recent or recurrent herpes zoster or herpes simplex viral infection” |
| Active or chronic infection | “Evidence of active infection or positive test result for hepatitis B, hepatitis C, HIV or TB” |
| Serious infection history | “History of serious bacterial, fungal, or viral infections that led to hospitalization, or any recent serious infection requiring antibiotic treatment” |
| Immunodeficiency | “Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status” |
| Laboratory abnormalities | “Lab abnormalities indicating significant renal, hepatic or bone marrow dysfunction” |
| Systemic corticosteroids | “History of any immune-mediated or inflammatory medical condition for which participants requires current systemic corticosteroids” |
| Inhaled corticosteroids | “Stable doses of inhaled corticosteroids for treatment of asthma are allowed” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-6"></a>

#### Malignancy, vaccination, surgery, and psychiatric exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Malignancy | “Known current malignancy or current evaluation for a potential malignancy or history of malignancy within the past 5 years prior to screening, except for adequately treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix” |
| Live vaccines | “Live vaccines within 4 weeks prior to Study Day 1” |
| Planned surgery | “Participant has planned surgery during the study period” |
| Unstable clinical condition | “Any acute or chronic illness/condition or evidence of an unstable clinical condition that, in the opinion of the Investigator, will substantially increase the risk to the participant if he or she participates in the study” |
| Mental illness | “History of mental illness within the last 5 years, unless receiving a fixed regimen of psychiatric medications for at least 6 months before screening or has not required or been prescribed any psychiatric medication within 12 months before screening” |
| Depression and suicidality | “Evidence of severe depressive symptoms or active suicidal ideation or behavior” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.4-7"></a>

#### Key inclusion and exclusion criteria for ONWARD1 and ONWARD2 in the topline webcast presentation

> “Total body weight >40 kg (88 lb )”
> “Diagnosis of plaque psoriasis for ≥6 months prior to the Screening Visit”
> “Plaques covering ≥10% of BSA at Screening and Day 1”
> “PASI ≥12 at Screening and Day 1”
> “sPGA ≥3 at Screening and Day 1”
> “Deemed by the Investigator to be a candidate for phototherapy or systemic therapy”
> “Non - plaque psoriasis​ (e.g., guttate, inverse, pustular, erythrodermic or other inflammatory skin conditions that may interfere with the study assessments)”
> “Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) or a cardiac hospitalization within the last 3 months”
> “Entry criteria reflects a moderate - to - severe plaque psoriasis adult population”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Quoted record |
| --- | --- |
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.5-2"></a>

#### Dose and randomization ratio across ONWARD1 and ONWARD2

> “More than 1,700 patients were enrolled and randomized 2:1:1 to receive envudeucitinib 40 mg twice daily, placebo, or apremilast.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.1.5-3"></a>

#### No fasting requirement in ONWARD1 and ONWARD2

> “The ONWARD clinical trials did not have a fasting requirement.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using PASI 75 and sPGA 0/1 Response as the Co-primary Endpoints

<a id="topic-3.1.1.6.1-1"></a>

##### Primary outcome in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary outcome measure | “To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo” |
| Measure description | “Proportion of participants achieving ≥75% reduction in PASI score. Proportion of participants achieving a score of 0 or 1 on sPGA.” |
| Time frame | “16 weeks” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.6.1-2"></a>

##### Secondary outcomes in the ClinicalTrials.gov record

| Secondary outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast” | “Proportion of participants achieving of ≥90% or 100% reduction in PASI” | “24 weeks” |
| “To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast” | “Proportion of participants achieving of ≥75% reduction in PASI” | “24 weeks” |
| “To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast” | “Proportion of participants achieving a score of 0 or 1 on sPGA” | “24 weeks” |
| “To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast” | “Change from baseline in %BSA” | “24 weeks” |
| “To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast.” | “Proportion of participants achieving a score of 0 or 1 on ssPGA” | “24 weeks” |
| “To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast” | “Proportion of participants achieving a score of 0” | “24 weeks” |
| “To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast” | “Proportion of participants achieving a score of 0 or 1” | “24 weeks” |
| “To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo” | “Change from baseline in Pruritus NRS” | “24 weeks” |
| “Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “24 weeks” |
| “To characterize the pharmacokinetics of ESK-001” | “Maximum [Cmax] and minimum [Cmin] plasma concentration” | “24 weeks” |

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.6.1-3"></a>

##### Planned co-primary endpoints of ONWARD1 and ONWARD2

> “The co-primary efficacy endpoints will be the proportion of patients with moderate-to-severe plaque psoriasis achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and sPGA score 0/1 of ESK-001 compared to placebo at Week 16.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.1.6.1-4"></a>

##### Co-primary, key secondary, and safety endpoints of ONWARD1 and ONWARD2 in the congress poster

> “Coprimary endpoints (vs placebo; PASI 75 and sPGA-0/1), key secondary endpoints (vs placebo or apremilast; PASI 75/90/100, sPGA-0/1, change from baseline in itch [NRS], ss-PGA-0/1 [baseline ≥3], and DLQI-0/1 [baseline ≥2]), and safety endpoints were assessed.”

Source: [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf)

<a id="topic-3.1.1.6.1-5"></a>

##### Definitions of PASI and sPGA response thresholds in the congress presentation

> “PASI 75/90/100, ≥75%/≥90%/100% improvement in PASI; PGA, Physician’s Global Assessment; sPGA, static PGA; sPGA-0/1, sPGA 0 (clear) or 1 (almost clear); ss-PGA-0/1, scalp-specific PGA 0 (clear) or 1 (almost clear)”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.6.1-6"></a>

##### Regulatory guidance on PASI as a primary endpoint and its pairing with a global score

> “PASI score has been the most frequently used primary endpoint in therapeutic confirmatory trials both for topical and systemic agents.”
> “It is considered that PASI alone is not sufficient to evaluate psoriasis severity at baseline and on treatment.”
> “Therefore, it is strongly recommended to use two endpoints to assess efficacy: a validated, standardised global score (e.g. PGA) in conjunction with PASI.”

Source: [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 912”

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment at registration

> “Enrollment 840 [Estimated]”

Source: [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)

<a id="topic-3.1.1.7.1-3"></a>

##### Planned enrollment of approximately 840 participants per trial

> “Each trial will enroll approximately 840 patients randomized 2:1:1 to receive either ESK-001 40 mg twice-daily, placebo or apremilast.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants by arm in ONWARD1 and ONWARD2

> “Envudeucitinib 40 mg BID (n = 459; 433)”
> “Placebo (n = 230; 211)”
> “Apremilast 30 mg BID (n = 223; 215)”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

> “ONWARD1/2: N=1771 (envudeucitinib n=459, 433; placebo n=230, 211, apremilast n=223, 215, respectively).”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Intention-to-treat analysis of response endpoints in ONWARD1 and ONWARD2

> “Intention-to-treat population. The 95% CIs and P-values of the treatment differences were based on the Cochran-Mantel-Haenszel test adjusted for stratification factors. Nonresponder imputation was applied for missing data.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Mixed model for repeated measures for itch in ONWARD1 and ONWARD2

> “Intention-to-treat population. LSMs, CIs, and P-values are based on MMRM.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Pooled safety analysis population of ONWARD1 and ONWARD2

> “Safety analysis population; pooled ONWARD1 and ONWARD2 data.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Baseline demographics and disease characteristics by arm in ONWARD1

| Characteristic | Envudeucitinib 40 mg BID, n = 459 | Placebo, n = 230 | Apremilast 30 mg BID, n = 223 |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “49.1 (13.4)” | “49.2 (13.3)” | “47.7 (11.8)” |
| Age group, ≥65 years, n (%) | “61 (13.3)” | “27 (11.7)” | “15 (6.7)” |
| Sex, male, n (%) | “300 (65.4)” | “156 (67.8)” | “152 (68.2)” |
| Race, White, n (%) | “358 (78.0)” | “182 (79.1)” | “177 (79.4)” |
| Race, Asian, n (%) | “68 (14.8)” | “28 (12.2)” | “30 (13.5)” |
| Race, other, n (%) | “33 (7.2)” | “20 (8.7)” | “16 (7.2)” |
| Weight, kg, mean (SD) | “90.4 (24.0)” | “91.0 (24.3)” | “88.9 (21.0)” |
| BMI, kg/m2, mean (SD) | “30.6 (7.2)” | “30.6 (7.2)” | “29.8 (6.5)” |
| Duration of disease, years, mean (SD) | “19.9 (13.5)” | “19.5 (13.3)” | “17.2 (11.8)” |
| PASI, mean (SD) | “20.4 (8.0)” | “19.9 (7.5)” | “20.3 (6.9)” |
| sPGA of 4, n (%) | “129 (28.1)” | “57 (24.8)” | “61 (27.4)” |
| BSA % affected, mean (SD) | “25.8 (15.8)” | “26.2 (16.0)” | “25.2 (14.9)” |
| DLQI, mean (SD) | “10.6 (6.5)” | “10.1 (6.7)” | “10.8 (6.8)” |
| Worst pruritus NRS, mean (SD) | “6.1 (2.7)” | “6.0 (2.7)” | “6.3 (2.6)” |
| Prior systemic psoriasis treatment, n (%) | “221 (48.1)” | “113 (49.1)” | “107 (48.0)” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Balance across arms and definitions of other race and prior systemic treatment in the ONWARD1 and ONWARD2 baseline table

> “Baseline Demographics and Disease Characteristics Were Balanced Across Arms and Representative of a Typical Moderate-to-Severe Population”
> “Includes Black or African American, Native Hawaiian or Other Pacific Islander, American Indian or Alaska Native, and Other or not reported.”
> “Any prior exposure to systemic therapies for psoriasis (excluded phototherapy); all patients were required to meet protocol-defined exclusion and washout criteria prior to Study Day 1.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Baseline itch and scalp involvement by arm in ONWARD1

| Characteristic | Envudeucitinib 40 mg BID, N = 459 | Placebo, N = 230 | Apremilast 30 mg BID, N = 223 |
| --- | --- | --- | --- |
| Worst pruritus NRS ≥1, n (%) | “420 (91.5)” | “210 (91.3)” | “210 (94.2)” |
| Worst pruritus NRS ≥4, n (%) | “353 (76.9)” | “175 (76.1)” | “176 (78.9)” |
| ss-PGA ≥3, n | “274” | “135” | “150” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “213 (77.7)” | “102 (75.6)” | “124 (82.7)” |

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Baseline characteristics averaged across ONWARD1 and ONWARD2, including prior systemic and prior biologic use

> “Data based on average from both studies”
> “64 - 67% Male”
> “79 - 89% White”
> “33 - 38% United States”
> “Duration of Psoriasis Diagnosis ~19 years”
> “Over 40% prior systemic use”
> “Approximately 25% prior biologic use”
> “Mean PASI ~20; approximately 40% of patients having a PASI score >20”
> “sPGA of 3 in 70 - 73% of patients; sPGA of 4 in 27 - 30% of patients”
> “Mean BSA of 26%”

Source: [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Co-primary and secondary endpoint results of ONWARD1 and ONWARD2 at topline

> “Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2.”
> “In each of these trials, envudeucitinib achieved superior skin clearance compared with placebo (p < 0.0001) on the co-primary endpoints of Psoriasis Area and Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0/1 at Week 16.”
> “On average across both ONWARD1 and ONWARD2, 74% of patients achieved PASI 75 and 59% of patients achieved sPGA 0/1, with responses deepening over time.”
> “In addition, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.”
> “At Week 24, on the higher hurdle skin clearance measures, approximately 65% of patients achieved PASI 90, and more than 40% achieved PASI 100, on average across both trials.”
> “Rapid responses were observed, with clear separation from placebo on PASI 90 as early as Week 4.”
> “Envudeucitinib also achieved superior skin clearance compared with apremilast in each trial (p<0.0001) on all PASI endpoints at Week 24.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

<a id="topic-3.1.1.8.3-2"></a>

##### PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD1

| Week 16 response, % | Envudeucitinib 40 mg BID, n = 459 | Placebo, n = 230 | Apremilast 30 mg BID, n = 223 |
| --- | --- | --- | --- |
| PASI 75 (co-primary endpoint) | “76.5” | “18.7” | “44.4” |
| PASI 90 | “59.9” | “4.8” | “21.5” |
| PASI 100 | “29.4” | “0.9” | “4.0” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.3-3"></a>

##### PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD1

| Week 24 response, % | Envudeucitinib 40 mg BID, n = 459 | Apremilast 30 mg BID, n = 223 |
| --- | --- | --- |
| PASI 75 | “78.6” | “46.2” |
| PASI 90 | “68.0” | “25.6” |
| PASI 100 | “41.0” | “8.5” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.3-4"></a>

##### PASI 90 and PASI 100 response rates by trial at weeks 16 and 24 in ONWARD1 and ONWARD2

> “Psoriasis Area and Severity Index (PASI) 90 responses, which emerged as early as Week 4, were achieved by 59.9% and 53.1% of envudeucitinib patients at Week 16 (and by 4.8% and 4.3% of placebo patients), increasing to 68.0% and 62.1% at Week 24.”
> “PASI 100 responses followed a similar trajectory, with 29.4% and 27.7% of envudeucitinib patients achieving complete skin clearance at Week 16 (as compared to 0.9% and 0.9% of placebo patients), rising to 41.0% and 39.5% at Week 24.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.3-5"></a>

##### PASI, sPGA, and onset of response in ONWARD1 and ONWARD2 in the congress presentation

> “Almost 30% of patients receiving envudeucitinib achieved PASI 100 at Week 16”
> “Approximately 65% and 40% of patients achieved PASI 90 and PASI 100 with envudeucitinib at Week 24”
> “Early onset of action: separation vs placebo observed at Week 4”
> “Approximately 40% complete skin clearance at Week 24 without evidence of plateau”
> “Approximately 60% and 30% of patients receiving envudeucitinib achieved sPGA-0/1 and sPGA-0 at Week 16, and responses continued to improve through Week 24”
> “All primary and secondary efficacy endpoints met, with approximately 65% and 40% of patients receiving envudeucitinib achieving PASI 90 and PASI 100 at Week 24”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.3-6"></a>

##### Scalp psoriasis response (ss-PGA 0/1) at weeks 4 and 24 in ONWARD1 and ONWARD2

> “At Week 24, approximately three out of four envudeucitinib patients”
> “achieved clear or almost clear scalp psoriasis, measured by the Scalp Specific Physician’s Global Assessment (ss-PGA 0/1), with over 30% responding as early as Week 4.”
> “Based on patients with baseline ss-PGA ≥3”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.3-7"></a>

##### Treat-to-target PASI and BSA thresholds in a post hoc analysis of ONWARD1 and ONWARD2

> “To evaluate the achievement of clinically relevant treat-to-target thresholds for PASI and BSA in a post hoc analysis of ONWARD1 and ONWARD2”
> “Absolute PASI thresholds (0, ≤1, and ≤3) and BSA (≤3% and ≤1%) were calculated post hoc and assessed at Week 16 (vs placebo and apremilast) and Week 24 (vs apremilast)”
> “Patients who discontinued or had missing data were imputed as nonresponders”
> “Least squares (LS) means and corresponding 95% CIs for percent change from baseline in PASI total score were estimated using a mixed model with repeated measures (MMRM) with modified baseline observation carried forward (mBOCF) imputation; nominal P-values for treatment comparisons are presented at Weeks 16 and 24”
> “At Week 16, significantly more patients treated with envudeucitinib achieved clinically meaningful PASI treatment targets (Figure 3) and BSA treatment targets (Figure 4) vs placebo and apremilast”
> “Responses continued to improve through Week 24 for all thresholds”
> “Improvement in PASI from baseline with envudeucitinib was evident at Week 2 (Figure 6)”
> “Patients receiving envudeucitinib met stringent treat-to-target thresholds associated with disease control, with response rates increasing from Weeks 16 to 24”

Source: [Ehst et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-treattotarget-fall-clinical.pdf)

<a id="topic-3.1.1.8.3-8"></a>

##### Efficacy by prior biologic exposure or body weight

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

##### Quality of life (DLQI 0/1) by week 12 in ONWARD1 and ONWARD2 among participants with baseline DLQI of 2 or more

> “Approximately 50% of patients in ONWARD 1/2 achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1 by Week 12, reflecting minimal to no impact of psoriasis on daily activities.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

> “Envudeucitinib Treatment Significantly Improved Patient Quality of Life”
> “In patients with baseline DLQI ≥2.”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.4-2"></a>

##### Mean change in worst pruritus NRS by week 12 and by week 16, and timing relative to PASI 90, in ONWARD1 and ONWARD2

> “On average ˃4-point mean decrease from baseline in worst pruritus NRS by Week 12, with continued symptom improvement over time”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

> “By Week 16, envudeucitinib patients achieved an average improvement of more than 4 points from baseline on the 0–10 Worst Pruritus Numeric Rating Scale (NRS), with clinically meaningful itch relief as early as Week 2—one of the most burdensome symptoms of psoriasis.”
> “Notably, quality-of-life and itch improvements appeared before PASI 90 skin clearance responses and continued to deepen through Week 24 across both trials.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.4-3"></a>

##### Itch endpoints and methods in the ONWARD1 and ONWARD2 itch analysis

> “To evaluate the onset, magnitude, and durability of itch improvement with envudeucitinib, including among patients with scalp involvement, in ONWARD1 and ONWARD2”
> “Worst pruritus was assessed using a self-administered numeric rating scale (NRS, 0–10), reflective of the prior 24 hours”
> “Clinically meaningful improvement (≥4-point reduction from baseline) in worst pruritus NRS”
> “Among patients with baseline scalp-specific Physician’s Global Assessment (ss-PGA) ≥3 and worst pruritus NRS ≥4”
> “Worst pruritus NRS 0 with ≥1-point improvement”
> “Worst pruritus NRS 0/1 with ≥1-point improvement”
> “Confidence intervals (CIs) were obtained using Clopper–Pearson methods, and the 95% CIs and P-values of the treatment differences were calculated using the Cochran–Mantel–Haenszel test adjusted for stratification factors with nonresponder imputation. P-values are nominal”

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="topic-3.1.1.8.4-4"></a>

##### Itch response at week 2, itch resolution at week 16, and responses through week 24 in ONWARD1 and ONWARD2

> “Approximately one-third of patients receiving envudeucitinib reported a clinically meaningful ≥4-point improvement in worst pruritus NRS at Week 2 (Figure 3)”
> “Patients transitioning from placebo to envudeucitinib at Week 16 also reported rapid improvements in their worst pruritus NRS”
> “Improvements in patients with moderate-to-severe scalp psoriasis were consistent with improvements observed in the overall population (Figure 4)”
> “By Week 16, over one-third of patients receiving envudeucitinib achieved complete itch resolution (NRS 0; Figure 5) and more than half achieved minimal itch (NRS 0/1; Figure 6)”
> “All reported itch responses continued to improve with envudeucitinib treatment through Week 24 (Figures 3–6)”

Source: [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

> “In ONWARD 1/2, approximately one-third of patients—including those with moderate-to-severe scalp disease (ss-PGA ≥3)—achieved clinically meaningful itch reduction (≥4-point NRS improvement) as early as Week 2.”
> “By Week 16, about 40% reached complete itch resolution (NRS 0) and approximately 60% reported minimal or no itch (NRS 0/1).”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Pooled ONWARD1 and ONWARD2 adverse events through weeks 16 and 24

| Outcome, n (%) | Week 16: envudeucitinib 40 mg BID, n = 890 | Week 16: placebo, n = 441 | Week 16: apremilast 30 mg BID, n = 438 | Week 24: envudeucitinib 40 mg BID only, n = 890 | Week 24: placebo to envudeucitinib 40 mg BID, n = 390 | Week 24: overall envudeucitinib 40 mg BID, n = 1280 | Week 24: apremilast 30 mg BID, n = 438 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| At least 1 TEAE | “524 (58.9)” | “166 (37.6)” | “223 (50.9)” | “563 (63.3)” | “130 (33.3)” | “693 (54.1)” | “248 (56.6)” |
| At least 1 SAE | “19 (2.1)” | “5 (1.1)” | “5 (1.1)” | “24 (2.7)” | “1 (0.3)” | “25 (2.0)” | “6 (1.4)” |
| TEAE leading to treatment discontinuation | “30 (3.4)” | “7 (1.6)” | “9 (2.1)” | “31 (3.5)” | “4 (1.0)” | “35 (2.7)” | “12 (2.7)” |
| TEAE grade ≥3 | “42 (4.7)” | “14 (3.2)” | “18 (4.1)” | “48 (5.4)” | “7 (1.8)” | “55 (4.3)” | “23 (5.3)” |
| Nasopharyngitis | “64 (7.2)” | “21 (4.8)” | “16 (3.7)” | “92 (10.3)” | “18 (4.6)” | “110 (8.6)” | “26 (5.9)” |
| Headache | “92 (10.3)” | “11 (2.5)” | “40 (9.1)” | “97 (10.9)” | “11 (2.8)” | “108 (8.4)” | “42 (9.6)” |
| Upper respiratory tract infection | “43 (4.8)” | “7 (1.6)” | “16 (3.7)” | “57 (6.4)” | “2 (0.5)” | “59 (4.6)” | “21 (4.8)” |
| Acne | “53 (6.0)” | “3 (0.7)” | “3 (0.7)” | “60 (6.7)” | “17 (4.4)” | “77 (6.0)” | “3 (0.7)” |
| Nausea | “20 (2.2)” | “4 (0.9)” | “23 (5.3)” | “20 (2.2)” | “0” | “20 (1.6)” | “23 (5.3)” |
| Diarrhea | “14 (1.6)” | “11 (2.5)” | “36 (8.2)” | “16 (1.8)” | “1 (0.3)” | “17 (1.3)” | “36 (8.2)” |

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.5-2"></a>

##### Deaths, MACE, cytopenias, tuberculosis, laboratory findings, serious infections, and malignancies in pooled ONWARD1 and ONWARD2

> “TEAEs occurring in ≥5% of patients in any treatment arm through either Week 16 or Week 24.”
> “Envudeucitinib showed low rates of SAEs and AEs leading to discontinuation, with no clusters of events”
> “No deaths; no MACE or cytopenia signals; no TB reactivation”
> “Thirty-nine patients with latent or treated TB were enrolled.”
> “No clinically significant laboratory abnormalities were observed across lipid, hematologic and chemistry panels, with comparable variability across treatment arms throughout the study”
> “At Week 24, low incidence of serious infections (0.7%) and malignancies (0.2%) observed in patients treated with envudeucitinib”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

<a id="topic-3.1.1.8.5-3"></a>

##### Tolerability and most common adverse events in ONWARD1 and ONWARD2 through week 24

> “Treatment with envudeucitinib was generally well tolerated through Week 24 in both trials, with a safety profile consistent with the Phase 2 program, including its long-term extension study.”
> “No clinically significant laboratory abnormalities or cases of tuberculosis reactivation were observed.”
> “Treatment-emergent adverse events were mostly mild, transient, self-limited, or responding to standard therapy, with the most common being headache, nasopharyngitis, upper respiratory tract infection, and acne.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-3.1.1.8.5-4"></a>

##### Similar adverse event frequency and severity between ONWARD1 and ONWARD2

> “Treatment-emergent adverse event (TEAE) frequency and severity were similar across trials, with the majority being mild to moderate, transient, and responding to standard therapy, if required.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

<a id="topic-3.1.1.8.5-5"></a>

##### Herpes zoster and creatine phosphokinase elevations

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- ONWARD1 results are available from company press releases, a company webcast presentation, and congress materials (Blauvelt et al., Hawkes et al., Ehst et al.). The ClinicalTrials.gov record reads “No Results Posted” and records a certification/extension first submitted on 2026-08-06.
- Placebo control lasted 16 weeks, after which placebo participants rolled over to envudeucitinib; the week 24 PASI results compare envudeucitinib with apremilast alone.
- The report holds no participant disposition by arm, no efficacy by prior biologic exposure or body weight, and no herpes zoster or creatine phosphokinase data. Safety, itch, and DLQI results are reported only for ONWARD1 and ONWARD2 pooled.
- The sources differ on itch: the congress presentation places the mean decrease of more than 4 points in worst pruritus NRS by week 12 and a press release by week 16; at week 16, NRS 0 is reported as over one-third (itch poster) and about 40% (press release), and NRS 0/1 as more than half and approximately 60%.
- Prior treatment is reported on different measures: prior systemic treatment by arm in 221 (48.1%), 113 (49.1%), and 107 (48.0%) participants (congress presentation), and, averaged across both trials, “Over 40% prior systemic use” and approximately 25% prior biologic use (webcast presentation). The report holds no prior biologic use by arm.
- The itch analysis reports nominal P-values, and the PASI and BSA treat-to-target thresholds were calculated post hoc.
- Eligibility excluded participants with lack of clinical response to a TYK2, IL-12, or IL-23 targeted treatment and those with recent or recurrent herpes zoster or herpes simplex infection.
- The webcast presentation lists Belgium among the countries of study ESK-001-016, and the ClinicalTrials.gov API record for NCT06586112 lists Belgium as a removed location country.

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [ClinicalTrials.gov NCT06586112 API record](https://clinicaltrials.gov/api/v2/studies/NCT06586112); [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf); [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf); [Ehst et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-treattotarget-fall-clinical.pdf); [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib); [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
